Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study

Authors:

Abstract
: BI 695501 is an approved biosimilar to Humira® reference product (RP). : In this randomized Phase III trial (VOLTAIRE-PSO), patients with moderate-to-severe chronic plaque psoriasis received BI 6...
Funding Information
  • Boehringer Ingelheim

This publication has 19 references indexed in Scilit: